ClinicalTrials.gg
Not yet recruitingNCT06749093WADEUpdated Dec 27, 2024

Health Effects of Wood Smoke and Traffic-Related Air Pollution Exposures: a Necessary Comparison

An interventional study of Filtered Air (FA) and Wood Smoke (WS) in Healthy Individuals and Allergic Rhinitis, sponsored by University of British Columbia. Not yet recruiting at 1 site in Canada. Open to participants aged 19 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by University of British Columbia · Not applicable, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
19 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Rhinitis, Allergic with a site in Canada — 3 open to participants now, 7 under way, none of them phase 3. Rhinitis, Allergic · Canada.

Planned enrollment
26th of 45
48 · median 60
Started
2025
with 1 other
No phase
10 of 49
1 open now
Registered
46th of 49
by date
Lead sponsor
3 of 49
University of British Columbia

Among the 49 studies in Rhinitis, Allergic with a site in Canada, this one is the 26th largest by planned enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 with no phase, and was the 46th registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

3 of the 49 studies in Rhinitis, Allergic with a site in Canada are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 19 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Rhinitis, Allergic with a site in Canada, or all of them as a file.
02

Study summary

Accumulating evidence demonstrates that breathing air pollutants leads to devastating increases in sickness and death worldwide over time. However, there is little data comparing the effects of different types of air pollution on health. In Canada, traffic-related air pollution and wood smoke (wildfires and wood burning for heating) are very common air pollutants. This study aims to safely complete a controlled human exposure study to test how these air pollution types acutely affect health.

Read the detailed description

Healthy adult participants (total 48; 24 of each biological sex assigned at birth) will breathe filtered air (control), wood smoke (WS), diesel exhaust (DE), and DE plus WS (DEWS) each for 2 hours, with 4 weeks between each exposure (washout). Before and after each exposure, participants will answer questions, perform breathing tests, and give blood samples. At 24 hours after each exposure, participants will undergo a bronchoscopy to collect samples from their lungs.

The study will look at what (if any) are the differences between breathing in fresh air (filtered air - FA) or polluted air containing either wood smoke (WS), diesel exhaust (DE) or diesel exhaust plus wood smoke (DEWS). The research team will use wood smoke generated from pine wood, since it is one of the most common types of wood found in Western Canadian forests where forest fires occur.

The investigators will evaluate multiple endpoints as detailed in the Outcome Measures section. For each applicable endpoint, the investigators will evaluate stratified analyses and effect modification by biological sex, participant age, gene score, and microbiomes.

03

Conditions studied

  • Healthy Individuals
  • Allergic Rhinitis

Browse trials for

Keywords

  • Air Pollution
  • Wood Smoke
  • Diesel Exhaust
04

Who can participate

Ages eligible
19 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 19-40
  • Healthy, with no history of respiratory disease
  • Lifetime non-smoker and non-vaper.

Exclusion criteria

Exclusion Criteria:

  • Pregnant, planning to become pregnant, or breastfeeding during the study period (confirmed through pregnancy tests at each visit if applicable)
  • Frequent WS or DE exposures (e.g. home fireplace used for heating/cooking, or employment in transportation, mining, or as a firefighter).
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Placebo comparator
    Filtered Air (FA)

    Participants will be exposed to 2 hours of high-efficiency particulate air (HEPA) filtered air (FA).

    Other: Filtered Air (FA)

  • Active comparator
    Wood Smoke (WS)

    Participants will be exposed to 2 hours of controlled wood smoke (WS) standardized to 300ug/m\^3 of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).

    Other: Wood Smoke (WS)

  • Active comparator
    Diesel Exhaust (DE)

    Participants will be exposed to 2 hours of controlled diesel exhaust (DE) as a model of traffic-related air pollution (TRAP) standardized to 300ug/m\^3 of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).

    Other: Diesel Exhaust (DE)

  • Active comparator
    Diesel Exhaust and Wood Smoke (DEWS)

    Participants will be exposed to 2 hours of combined controlled diesel exhaust (DE) and wood smoke (DEWS) standardized to 300ug/m\^3 of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).

    Other: Diesel Exhaust and Wood Smoke (DEWS)

Interventions

  • OtherFiltered Air (FA)

    Exposure to HEPA filtered air, as a control

  • OtherWood Smoke (WS)

    Wood smoke (WS) standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).

  • OtherDiesel Exhaust (DE)

    Diesel exhaust (DE) standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).

    Also known as: Traffic-Related Air Pollution

  • OtherDiesel Exhaust and Wood Smoke (DEWS)

    Combined diesel exhaust and wood smoke standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).

    Also known as: Air Pollution

06

What researchers measure

Primary outcomes

  1. Woodsmoke (WS) and/or diesel exhaust (DE) exposure effects on inflammatory cells in the lungs.

    Differentially count lung cells.

    Time frame: Comparison of the different arms (over the span of ~5 months).

  2. Within-individual change in lung transcriptomic biomarkers of inflammation following exposure to woodsmoke and/or diesel exhaust.

    Within-individual change in lung biomarkers of inflammation (serum amyloid A (SAA), c-reactive protein (CRP), chemokine ligand 18 (CCL18), and fibrinogen) in RNA.

    Time frame: Through study completion, anticipated ~5 months.

  3. Within-individual change in lung protein biomarkers of inflammation following exposure to woodsmoke and/or diesel exhaust.

    Within-individual change in lung biomarkers of inflammation (serum amyloid A (SAA), c-reactive protein (CRP), chemokine ligand 18 (CCL18), and fibrinogen) in protein.

    Time frame: Through study completion, anticipated ~5 months.

  4. Within-individual change in circulating transcriptomic biomarkers of inflammation following exposure to woodsmoke and/or diesel exhaust.

    Within-individual change in circulating biomarkers of inflammation (CX3CL1, CCL23, CXCL8, SAA, MMP9, MMP12, APOB, APOM, SOD1, NQO1, HMOX1, CAT, CYP1B1, CYP1A2, NFE2L2 and AHRR) in RNA.

    Time frame: Through study completion, anticipated ~5 months.

  5. Within-individual change in circulating protein biomarkers of inflammation following exposure to woodsmoke and/or diesel exhaust.

    Within-individual change in circulating protein biomarkers of inflammation (CX3CL1, CCL23, CXCL8, SAA, MMP9, MMP12, APOB, APOM, SOD1, NQO1, HMOX1, CAT, CYP1B1, CYP1A2, NFE2L2 and AHRR).

    Time frame: Through study completion, anticipated ~5 months.

  6. Within-individual change in airway resistance following exposures to woodsmoke and/or diesel exhaust.

    Within-individual change in airway resistance, as measured by impulse oscillometry (resonant frequency (Fres) and peripheral airway resistance (R5-R20)) across exposures to woodsmoke and/or diesel exhaust relative to filtered air.

    Time frame: Through study completion, anticipated ~5 months.

Secondary outcomes

  1. Woodsmoke (WS) and/or diesel exhaust (DE) exposure effects on inflammatory cells in the nose.

    Differentially count nasal cells.

    Time frame: Comparison of the different arms (over the span of ~5 months).

  2. Within-individual changes in exhaled nitric oxide following woodsmoke (WS) and/or diesel exhaust (DE) exposures.

    Measurement of fractional exhaled nitric oxide (FeNO) in parts per billion (ppb).

    Time frame: Comparison of the different arms (over the span of ~5 months).

  3. Woodsmoke (WS) and/or diesel exhaust (DE) exposure effects on symptoms, stress and perceptions.

    Visual analog score (0-100) questionnaire will be completed, with a higher score indicating a worse outcome.

    Time frame: Comparison of the different arms (over the span of ~5 months).

  4. Woodsmoke (WS) and/or diesel exhaust (DE) exposure effects on lung function.

    Lung function as evaluated by spirometry (e.g. FEV1).

    Time frame: Comparison of the different arms (over the span of ~5 months).

  5. Woodsmoke (WS) and/or diesel exhaust (DE) exposure effects on nasal resistance.

    Measurement of peak nasal inspiratory flow (PNIF).

    Time frame: Comparison of the different arms (over the span of ~5 months).

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Participant data that underlie the results reported in accepted articles for publications, after deidentification (text, tables, figures, and appendices).

Time frame: Immediately following publication. No end date.

Access criteria: Researchers who provide a methodologically sound proposal to the PI to complement the approved study aims.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Dec 2026, 17 months later.

Of 66 non-industry interventional studies with no phase under Rhinitis, Allergic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 17 months is above that.

Counting every sponsor, half of 87 studies reached it within 11 months; a quarter within 4 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2024
First posted
Dec 27, 2024
StartEst.
Jul 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2029
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06749093
Responsible party
Christopher Carlsten (Professor, University of British Columbia) — Principal investigator
First posted
Dec 27, 2024
Start date
Jul 1, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Dec 27, 2024

Study contacts

Agnes Yuen
Contact
agnes.yuen@ubc.ca
604-875-4111 ext. 66455
Parteek Johal
Contact
604-875-5132
Chris Carlsten, MD
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion